CancerVax Corporation to Host Webcast on Saturday, June 5 at 12:45 p.m. Central Time.Business Editors/Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--June 3, 2004 CancerVax Corporation (Nasdaq:CNVX), a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer, announced today the Company will host a live webcast on Saturday, June 5, 2004 at 12:45 p.m. Central Time (1:45 p.m. Eastern/10:45 a.m. Pacific). Special guest speakers include Eric Rowinsky, M.D., Senior Scientist at the Institute for Drug Development of the Cancer Therapy and Research Foundation and Clinical Professor of Medicine, Division of Medical Oncology at the University of Texas Health Science Center, who will discuss the role of the epidermal growth factor receptor This article is about a cell suface receptor. For estimated measure of kidney function (eGFR), see Glomerular filtration rate. The epidermal growth factor receptor (EGFR EGFR Epidermal Growth Factor Receptor (a kinase enzyme) EGFR Estimated Glomerular Filtration Rate ) signaling pathway and its role in cancer. In addition, Donald L. Morton, M.D., Medical Director and Surgeon-in-Chief of the John Wayne Cancer Institute, will discuss Canvaxin(TM), a specific active immunotherapy active immunotherapy The administration of substances to evoke a protective immune response in the form of specific antibodies. Cf Passive immunotherapy, Vaccine. approach to the treatment of advanced-stage melanoma. The final speaker will be David F. Hale, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CancerVax, who will provide a corporate update. To access the live webcast, please visit the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of the CancerVax website at http://ir.cancervax.com. The webcast will be archived on this site for 60 days. About CancerVax Corporation (www.cancervax.com) CancerVax Corporation is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. The Company's lead product candidate, Canvaxin(TM), is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines. Canvaxin(TM) is currently being studied in two international Phase 3 clinical trials for the treatment of patients with Stage III or Stage IV, or advanced-stage, melanoma. The Company is also finalizing the design of exploratory Phase 2 clinical trials for patients with metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colon cancer and, potentially, other advanced-stage solid tumors. In addition to Canvaxin(TM), the Company plans to identify and develop new product candidates based on its proprietary specific active immunotherapy, anti-angiogenesis and T-oligonucleotide, or telomere telomere /telo·mere/ (tel´o-mer) an extremity of a chromosome, which has specific properties, one of which is a polarity that prevents reunion with any fragment after a chromosome has been broken. homolog hom·o·log n. Variant of homologue. oligonucleotide, technology platforms, as well as on its human monoclonal antibody technology. CancerVax's corporate headquarters and research and development facility is located in Carlsbad, California and its biologics manufacturing facility is located in the Los Angeles, California area. CancerVax(R) is a registered trademark of CancerVax Corporation. Canvaxin(TM) is a trademark of CancerVax Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion